( April 24, 2026, 8:55 AM EDT) -- SAN FRANCISCO — A California federal judge found that Eli Lilly and Co. established standing in its amended complaint alleging unfair competition and false advertising claims against a telehealth company that sells a compounded version of tirzepatide, a U.S. Food and Drug Administration-approved drug for diabetes and weight loss, and largely denied the company’s motion to dismiss....